HR Execs on the Move

Diffusion Pharmaceuticals

www.diffusionpharma.com

 
Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Robert Cobuzzi
 Chief Executive Officer Profile

Similar Companies

Bioniche Pharma

Bioniche Pharma is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chembio Diagnostic Systems

Chembio Diagnostic Systems, Inc. is a Medford, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Integrated Viral Protection

World-Leading Biodefense Indoor Air Protection System™ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...

Family Solutions USA

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.